Literature DB >> 15047784

Indications of immune protection from hepatitis C infection.

Campbell K Aitken1, Scott Bowden, Margaret Hellard, Nick Crofts.   

Abstract

Hepatitis C affects many millions of people worldwide and is at very high prevalence among people who inject drugs. In our study of hepatitis C virus (HCV) in the social networks of injecting drug users (IDUs), five IDUs with injecting careers of 9 years or more were HCV antibody and RNA negative. All injected frequently with HCV RNA-positive IDUs, and two had recently injected with the syringe of an RNA-positive IDU. Our data suggest the existence of immune protection from HCV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047784      PMCID: PMC3456145          DOI: 10.1093/jurban/jth088

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  2 in total

1.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

2.  Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.

Authors:  S A Villano; D Vlahov; K E Nelson; S Cohn; D L Thomas
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

  2 in total
  4 in total

1.  How can hepatitis C be prevented in the long term?

Authors:  Pedro Mateu-Gelabert; Carla Treloar; Víctor Agulló Calatayud; Milagros Sandoval; Juan Carlos Valderrama Zurián; Lisa Maher; Tim Rhodes; Samuel R Friedman
Journal:  Int J Drug Policy       Date:  2007-07-24

2.  Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007-2015.

Authors:  Brendan Jacka; Robert Kemp; Louisa Degenhardt; Amy Peacock; Philip Clare; Raimondo Bruno; Abhilash Dev; Oluwadamisola Sotade; Briony Larance
Journal:  Drug Alcohol Rev       Date:  2019-02-13

Review 3.  A review of network simulation models of hepatitis C virus and HIV among people who inject drugs.

Authors:  Meghan Bellerose; Lin Zhu; Liesl M Hagan; William W Thompson; Liisa M Randall; Yelena Malyuta; Joshua A Salomon; Benjamin P Linas
Journal:  Int J Drug Policy       Date:  2019-11-15

4.  Positive deviance control-case life history: a method to develop grounded hypotheses about successful long-term avoidance of infection.

Authors:  Samuel R Friedman; Pedro Mateu-Gelabert; Milagros Sandoval; Holly Hagan; Don C Des Jarlais
Journal:  BMC Public Health       Date:  2008-03-20       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.